Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis

Table 4 Proportion of days covered and discontinuation of tofacitinib during follow-up, by prior biologic history

	Overall	Biologic-naïve	1 prior biologic	≥ 2 prior biologic
	N = 225	N = 43	N = 92	N = 90
Proportion of days covered during 6-month follow-up
Mean (SD)	0.7 (0.3)	0.7 (0.3)	0.7 (0.3)	0.7 (0.3)
Median (IQR)	0.8 (0.5, 1.0)	0.8 (0.5, 1.0)	0.9 (0.5, 1.0)	0.8 (0.5, 1.0)
Discontinuation during 4 months of follow-up,^a n (%)	34 (15.1)	9 (20.9)	15 (16.3)	10 (11.1)
Time to discontinuation during 4 months of follow-up,^a days
Mean (SD)	42.4 (15.0)	43.3 (15.8)	42.0 (15.2)	42.0 (15.5)
Median (IQR)	30.0 (30.0, 60.0)	30.0 (30.0, 60.0)	30.0 (30.0, 60.0)	30.0 (30.0, 60.0)

Sensitivity analysis (12 months of follow-up)	N = 91	N = 16	N = 31	N = 44
Proportion of days covered during 12-month follow-up
Mean (SD)	0.7 (0.3)	0.8 (0.2)	0.7 (0.3)	0.6 (0.3)
Median (IQR)	0.8 (0.4, 1.0)	0.8 (0.6, 0.9)	0.8 (0.5, 1.0)	0.6 (0.3, 1.0)
Discontinuation during 10 months of follow-up,^a n (%)	36 (39.6)	4 (25.0)	10 (32.3)	22 (50.0)
Time to discontinuation during 10 months of follow-up,^a days
Mean (SD)	120.0 (67.8)	177.8 (61.7)	131.1 (72.0)	104.4 (62.8)
Median (IQR)	99.5 (63.5, 180.0)	198.0 (135.0, 220.5)	105.5 (90.0, 180.0)	94.5 (60.0, 150.0)

The ideal proportion of days covered is 1.0
IQR, interquartile range; SD, standard deviation
^aPatients were not considered at risk of discontinuing therapy in the last 60 days of their follow-up because of the required 60-day gap to define discontinuation. Therefore, discontinuation was only calculated up to 60 days before the end of the follow-up period

ISSN: 1471-230X